Genocea Biosciences Inc. (GNCA) Shares Up 5.3%
Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) shot up 5.3% during mid-day trading on Wednesday . The company traded as high as $4.20 and last traded at $4.19, with a volume of 113,984 shares. The stock had previously closed at $3.98.
A number of brokerages recently issued reports on GNCA. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a report on Friday, June 10th. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Buy” and an average price target of $18.13.
The firm’s market cap is $116.83 million. The firm’s 50 day moving average is $4.15 and its 200-day moving average is $4.28.
Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Thursday, May 5th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. Equities analysts forecast that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current year.
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.